BofA analyst Kevin Fischbeck raised the firm’s price target on Universal Health (UHS) to $190 from $165 and keeps an Underperform rating on the shares. The firm raised its 2025, 2026 and 2027 EBITDA estimates in keeping with guidance and applies a higher multiple to its new estimates given core acute business growth. However, the firm reiterates an Underperform rating as it sees UHS having above average exposure to policy changes while its core results “remain weak,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health’s Mixed Q3 Performance and Stable Outlook Justify Hold Rating
- Universal Health price target raised to $263 from $250 at Barclays
- Closing Bell Movers: Rambus slips 9%, F5 down 6% after Q3 earnings
- Universal Health reports Q3 adjusted EPS $5.69, consensus $4.95
- Universal Health raises FY25 adj EPS view to $21.50-$22.10 from $20.00-$21.00